| 1 | UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY | | | | | |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|
| 2 | JOHNSON & JOHNSON HEALTH . | | | | | |
| 3 | CARE SYSTEMS INC., . Case No. 22-CV-2632 Plaintiff, . | | | | | |
| 4 5 | . Newark, New Jersey vs August 16, 2022 | | | | | |
| 6 | SAVE ON SP, LLC, | | | | | |
| 7 | Defendant | | | | | |
| 8 | TRANSCRIPT OF HEARING | | | | | |
| 9 | BEFORE THE HONORABLE CATHY L. WALDOR UNITED STATES MAGISTRATE JUDGE | | | | | |
| 10 | APPEARANCES (the parties appeared via teleconference) | | | | | |
| 11 | For the Plaintiff: JEFFREY J. GREENBAUM, ESQ. Sills Cummis & Gross PC 1 Riverfront Plaza Newark, NJ 07102 (973) 643-7000 jgreenbaum@silliscummis.com | | | | | |
| 13 | | | | | | |
| 14 | | | | | | |
| 15 | KATHERINE M. LIEB, ESQ. Sills Cummis & Gross PC | | | | | |
| 16 | 1 Riverfront Plaza Newark, NJ 07102 | | | | | |
| 17 | (973) 643-7000 klieb@silliscummis.com | | | | | |
| 18 | | | | | | |
| 19 | | | | | | |
| 21 | Audio Operator: | | | | | |
| 22 | Transcription Service: KING TRANSCRIPTION SERVICES, LLC 3 South Corporate Drive, Suite 203 | | | | | |
| 23 | Riverdale, NJ 07457 (973) 237-6080 | | | | | |
| 24 25 | Proceedings recorded by electronic sound recording; transcript produced by transcription service. | | | | | |

Hearing 22-cv-2632, August 16, 2022 2 1 (APPEARANCES continued) 2 For the plaintiff: HARMAN AVERY GROSSMAN, ESQ. Assistant General Counsel 3 1 Johnson & Johnson Plaza New Brunswick, NJ 08933 4 (732) 524-2559 hgrossman@jnj.com 5 For the Defendant E. EVANS WOHLFORTH, JR, ESQ. 6 Save On LLC: Gibbons PC 1 Gateway Center 7 Newark, NJ 07102-5310 (973) 596-4879ewohlforth@gibbonslaw.com 8 9 MICHAEL V. CARACAPPA, ESQ. Gibbons PC 10 1 Gateway Center Newark, NJ 07102-5310 (973) 596-4879 11 mcaracappa@gibbonslaw.com 12 DAVID ELSBERG, ESQ. Selendy Gay Elsberg PLLC 13 1290 Avenue of the Americas 14 New York, NY 10104 (212) 390-9004 15 delsberg@selendygay.com 16 ANDREW R. DUNLAP, ESQ. Selendy Gay Elsberg PLLC 17 1290 Avenue of the Americas New York, NY 10104 18 (212) 390-9005adunlap@selendygay.com 19 MEREDITH NELSON, ESO. 20 Selendy Gay Elsberg PLLC 1290 Avenue of the Americas 21 New York, NY 10104 (212) 390-9069 22 mnelson@selendygay.com 23 24 25

| Case 2:22-0 | V-02632-CCC-CLW Hearing 22-cv-2632, August 16, 2022 | Document 44 | Filed 08/31/22 | | | |
|-------------|------------------------------------------------------|--------------------------------------------|--------------------------------|-------|--|--|
| 1 | (APPEARANCES continued) | | | | | |
| 2 | | | | | | |
| 3 | For the Aimed Alliance | AIMED A | ASHIRA VANTREES AIMED ALLIANCE | | | |
| 4 | | 1455 Pennsylvania Avenue, NW, Suite 400 | | | | |
| 5 | | Washington, DC (202) 349-4089 | ton, DC 20004 49-4089 | 20004 | | |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |
| 10 | | | | | | |
| 11 | | | | | | |
| 12 | | | | | | |
| 13 | | | | | | |
| 14 | | | | | | |
| 15 | | | | | | |
| 16 | | | | | | |
| 17 | | | | | | |
| 18 | | | | | | |
| 19 | | | | | | |
| 20 | | | | | | |
| 21 | | | | | | |
| 22 | | | | | | |
| 23 | | | | | | |
| 24 | | | | | | |
| 25 | | | | | | |

Hearing 22-cv-2632, August 16, 2022 1 (Commencement of proceedings) 2 THE COURT: All right. We're now on the record 22-2632. Johnson & Johnson versus Save On and 3 Jeff -- Mr. Greenbaum, if you wouldn't mind, 4 others. 5 could you enter plaintiff's appearances again, I'm 6 sorry. 7 MR. GREENBAUM: Not a problem. morning, Your Honor. Jeffrey J. Greenbaum and 8 Katherine Lieb of Sills Cummis and Gross for the 9 plaintiff, Johnson and Johnson Health Care Services 10 Inc. Along with me today is Mr. Adeel Mangi of 11 Patterson Belknap Webb and Tyler LLP and Harmon Avery 12 Grossman, Assistant General Counsel of Johnson and 13 14 Johnson. Mangi will be leading the discussion for the plaintiff. 15 16 THE COURT: Thank you. Who's on for Save On SP? 17 18 MR. WOHLFORTH: Good morning, Your Honor.

This is Evans Wohlforth from the Gibbons Firm. With me is Michael Caracappa also from -- from our firm. And from the Selendy, Gay and Elsberg firm, we have David Elsberg, Andrew Dunlap and Meredith Nelson. Mr. Dunlap will be bearing the flag for defendants today.

19

20

21

22

23

24

25

THE COURT: Okay. And Aimed Alliance.

MS. VANTREES: Hi. My name is Ashira

25

5

Hearing 22-cv-2632, August 16, 2022 Vantrees and I'm legal counsel as Aimed Alliance. 1 2 THE COURT: Okay. Anyone on from Chiesa? MR. GREENBAUM: I think Mr. Pearlson had a 3 conflict. They just entered their appearance 4 5 yesterday and he told me he has another --6 THE COURT: Okay. 7 MR. GREENBAUM: -- appearance right now with a court -- another court. 8 9 THE COURT: I know somebody will advise him of what occurred today and they'll be a transcript as 10 well. 11 So, why don't you, plaintiff, Mr. Mangi, 12 discuss with me what the problems, if any, that are 13 14 occurring in this case. MR. MANGI: Yes, Your Honor. Good morning. 15 16 So Your Honor, what brings us here today is that as a plaintiff, we have been seeking to hold a Rule 26(f) 17 18 conference with the defendant in order to get the initial conferrals leading to discovery underway. 19 20 But the defendant has refused to hold an 21 Rule 26(f) conference. So, that is the immediate problem that brings us here today. 22 23 And with your permission, I can give you a

little bit of context on that dispute and set forth why we think the Court should set a Rule 16 conference Hearing 22-cv-2632, August 16, 2022

date so that we can get promptly to a Rule 26(f) conferral.

THE COURT: Okay. Go ahead.

MR. MANGI: Thank you, Judge. So, let me start then, Your Honor, with -- with the background here. So, Johnson & Johnson Health Care Systems or -- or JJHCS, the plaintiff, filed this case on May 4th. So, that's more than three months ago, now.

And this is an important case, Judge, because it relates to patient assistance funds that our client makes available to patients specifically to help them afford their medications. And this is a program that relates to medications provided by the Johnson & Johnson family of companies.

So, at core, what we have alleged here is that these patient assistance funds which we make available for patients are being unlawfully seized by the defendant, Save On SP, through a scheme that we've alleged constitutes deceptive trade practices and that also tortiously interferes with the agreements we have with patients that relate to those patient assistance programs. And we've alleged, you know, significant ongoing harm both to patients and to Johnson & Johnson Health Care Systems.

So, you know, promptly after Save On's

counsel appeared, we sought to hold a Rule 26(f) conference. And of course, as the Court knows under Rule 26(f), that conference is supposed to occur as soon as practicable, is the language of the Rule.

And so in this case, when you date from defendant's first appearance, based on the interplay of Rule 16 and Rule 26, the parties were obligated to hold that Rule 26(f) conference no later than July 3rd which would have then led to a Rule 16 conference by July 24th.

Now, Save On notably did not file a motion to stay discovery. They still have not filed a motion to stay discovery. But they refused to hold the conference as I indicated.

Let me also note just rounding out the background there. You know, despite our desire to -to keep this case moving, we have, Judge, sought to
be, very reasonable on scheduling. So, even after
Save On availed itself of the two week automatic
extension, we consented to another thirty day
extension because they wanted to file their motion to
dismiss.

And so where things stand now procedurally is, that Save On filed a motion to dismiss on July 15th. We filed our opposition to that yesterday. And

Hearing 22-cv-2632, August 16, 2022

under an agreed upon schedule, Save On's reply is gonna be due on August 29th. So -- so that briefing is almost complete.

And as Your Honor saw from the docket, a number of patient advocacy groups have also now filed an *amicus* brief in support of our position that was filed yesterday by a collection of different patient groups that have an interest in this issue.

So, our position here, Judge, is really quite straightforward. We believe that discovery must get underway now. It's already been three months since we filed. And -- and certainly it should not await the resolution of the motion to dismiss.

Now, we think that flows quite naturally form the reading of the rules and the dates that come from Rule 16 and Rule 26 as I laid out a moment ago. And of course, as the Court well knows, there's -- there's no automatic stay of discovery generated by the filing of a motion to dismiss. The defendant would need to show good cause and merely filing a motion to dismiss doesn't do it. And of course, you know, motions to stay are disfavored in this district, in particular.

I would suggest, Judge, that that alone should be enough here. That should be dispositive

because there has been no application for a stay of discovery. So, absent that like in any other case, the parties must promptly hold a Rule 26(f) conference in compliance with the Rules.

On that point, the only thing we really heard back from Save On is a citation to a local Rule 16.1. And Save On contends that it's under no obligation to hold a conference with us until and unless the Court schedules a Rule 16 conference which it suggests should not be scheduled until after the motion to dismiss is decided.

So, in substance, what that comes down to is, Save On arguing its filed a motion to dismiss so therefore it's entitled to a stay of discovery. And of course, the law is -- is precisely the opposite.

So, you know, in terms of this motion, obviously, you know, Your Honor, I understand will not engage with the merits of that in any great detail now. But I'll -- I'll just flag a few quick points about it.

The first is, you know, I have set out in the brief we filed yesterday, Judge. We believe that motion is predicated largely on disputed issues of fact that go well beyond our pleading. That's just not permissible. And so we don't think that motion

even, frankly, gets out of the starting gate for that reason.

And, you know, Save On has noted in its letter to you that they have made an ERISA pre-emption argument. But frankly, we don't think that gets out of the starting gate either. Certainly it should not play any role on this issue here.

And -- and fundamentally, the very short version of that is ERISA preemption at core, is a doctrine that's designed to ensure that when employees are challenging health coverage decisions by their employers, they must do so under the ERISA statutory frame work which governs employee benefits.

But, you know, under the Third Circuit precedent, drug manufacturers like us and defendants, entities like Save On, neither side here is within the bounds of ERISA preemption. In fact, their program isn't even limited to employee provided health plans. And the Supreme Court made clear just a couple of years ago in -- in the Rutledge case that issues relating to cost allocation aren't subject to ERISA preemption in any event.

So, we don't think any of that really -certainly doesn't ground any -- any basis to -- to
hold off further on discovery beyond the three months

1 | we've already waited here.

And -- and let me also just add one other point, Judge, which is there's some very significant harmful conduct to patients that we have alleged here. And you know, we've set out in detail in our complaint how and why we think the scheme is particularly pernicious.

And you know, just to give you one example, you know, we've alleged that Save On is engineering a false denial for patients' prescriptions at the pharmacy in order to coerce them to sign up with its program. And you know, these are patients often suffering from very serious conditions.

And then Save On is threatening them with hugely inflated payment if they don't participate.

When it forces them into their scheme it's then jacking up the amounts that it draws down from our patient assistance programs intended for patients, taking a twenty-five percent cut of that, undisclosed to patients. And generally imperiling the -- the existence of these programs.

And -- and frankly, doing all of this in -- in a manner that we think runs fundamentally contrary to all of the governing statutes in this area including the Affordable Care Act.

So -- so, that -- that's the background here, Judge, and where this all comes from. Let me make one final point. Which is, you know, all that we are seeking at the moment is to have a Rule 26(f) conference. And have that lead to a Rule 16 conference.

And you know, if Save On wants to make a -a motion to stay discovery, we haven't sought to
preclude them from doing that. We would oppose it.
but -- but they could seek that relief. But what we
submit that they should not be allowed to do, is just
engage in self-help and pretend like, just because we
filed a motion to dismiss, you know, we don't have to
have a Rule 26(f) conference.

We served them with document requests at the very outset. And we're prepared to engage with them immediately to -- to talk about, you know, the protective order and ESI protocol and get that process underway. And we certainly think that should get underway now.

And so, we're asking the Court to set a Rule 16 conference promptly and that will trigger Save On's obligation to confer with us in advance. And hopefully then we can get this case promptly underway.

Unless Your Honor has questions, that is our

1 | position.

THE COURT: All right. Thank you. Evans -- I mean, Mr. Wohlforth, I thought you said Mr. Dunlap would be speaking.

UNIDENTIFIED MALE: Yes --

THE COURT: Hello.

MR. DUNLAP: This is -- this is Mr. Dunlap.

I am prepared to speak.

THE COURT: Okay. There's a glitch in the phone. I don't know what happened. But go ahead.

MR. DUNLAP: Thank you, Your Honor. So, this is Andrew Dunlap on behalf of Save On. And just at the outset, I'd like to correct what our friend on the other side said about us potentially engaging in self-help or not complying with the Rules.

Rule 16 allows local rules to modify the general Federal Rules. And the -- as Your Honor is likely aware, Local Rule 16.1 in this district gives you the discretion to schedule the Rule 16 conference up until sixty days within the filing of an answer. And even longer than that if there is a pending motion.

And so, I'd like to just address why we think the rule -- that you should not use your discretion to schedule the conference now. And then

1 | talk a little bit about the procedure.

So, there are three basic reasons we don't think discovery should go forward now. The first is that we do have a motion to dismiss on file that could dispose of all of Johnson & Johnson's claims here.

And -- and critically, we are moving on basis that J&J could not cure by amending.

So, just as background, Johnson & Johnson set up this co-pay assistance program, CarePath, that it says will cover up to \$20,000 of co-pays that commercial health plans require members to pay for Johnson & Johnson specialty drugs.

What my client Save On does is it advises those employers how to structure their plan terms so that the plans can take full advantage of the funds that J&J says that it's providing.

Now, J&J doesn't like these plan terms because they result in J&J paying out more money in co-pay assistance than it had been paying under prior terms. But that doesn't give J&J a cause of action here. And I don't want to go down too far into the merits.

But there are -- there is a very strong argument here that ERISA preempts substantially all of J&J's claims. The fact that J&J --

THE COURT: Yes, can you talk about that a little bit.

MR. DUNLAP: Sure. So, the ERISA preemption standard is not limited to employees. It is limited to state laws or it includes state laws, including state law causes of actions that would operate or force a change in the actual plans.

And the relief that J&J is seeking here which includes injunctive relief, would essentially force the plans that Save On advance -- advises to change their plan terms to get rid of those provisions that J&J doesn't like.

So, the way the plans work is, they designate certain drugs as -- under the ACA that allow them to then set co-pays at a certain level. That set co-pays at a high level. They then say if members sign up for co-pay assistance, that is if they enroll in a program like CarePath, then after they have exhausted all those funds, the plans will pay the rest.

So, the members who sign up for Johnson & Johnson's programs, under plans advised by Save On, they wind up paying nothing for their specialty drugs. All this talk that somehow patients are being harmed here, is simply incorrect even based on the documents

1 | that J&J cites in its own pleading.

What J&J is asking for here are changes that would prevent the plans from implementing those plan terms and hiring Save On to implement those plan terms, forcing it then to go back to the old terms that J&J wants. That is squarely within what ERISA preempts.

And if we're right about that, then virtually all of Save -- J&J's claims go away except for a very small piece that relate to non ERISA plaintiffs. And J&J can't plead around that. They cannot.

Another critical point here, Your Honor, is that we don't believe that J&J has failed to plead that Save On injured it. It's alleged injury here is that it is paying out more in co-pay assistance than it wants to.

But the reason J&J is paying more in co-pay assistance than it wants to is because of two factors.

One, it voluntarily sets a co-pay assistance program where it budgets a certain amount of co-pay assistance for patients who use its drugs.

And two, plans, health benefit plans, set terms that allow them to draw down more of those funds from the program that J&J set up. Save On doesn't set

1 | these plan terms. The plans do.

Save On advises the plans. But the plans are the ones that actually set what the plan terms are and how the benefits work. And Save On also doesn't set J&J's co-pay assistance budget. J&J does that.

If J&J wants to reduce how much it's paying under its CarePath program, it could reduce that budge tomorrow and bring its costs down. This is not a legally cognizable injury caused by Save On to J&J. Which we think disposes of its other claims even without ERISA preemption.

And again, this is not something that J&J can plead around. We believe our motion is very likely to dispose of all of J&J's claims. And at a minimum, it could significantly reduce the scope of those claims. Which is why we don't believe it would be appropriate for discovery to go forward until this dispositive motion is resolved.

Now there are two other points I'd like to make briefly, if I could. Unless Your Honor has questions about that -- that point.

THE COURT: No. I'm -- I'm good so far.

And I think I know what path I want to take. But go ahead.

MR. DUNLAP: All right. Well, there are two

other points I'd like to make. One is that waiting until the motion is decided to advance discovery won't prejudice J&J in anyway. We're preserving relevant documents. There's no risk of any evidence being lost here.

There's absolutely nothing in the case that requires urgent discovery. Save On's operations are not new. They've been in business for years before J&J decided to sue it a few months ago. This is not some new conduct that requires an urgent investigation.

While they're moving for injunctive relief, they haven't moved for a TRO or for a preliminary injunction that would require some sort of immediate discovery. They haven't articulated any financial burden from waiting to have discovery til after the motion is resolved.

And contrary to what they're saying, there's no evidence that any patient is being de -- denied any kind of required medication because of what Save On is doing. To the contrary, Save On helps patients get those drugs at no cost because of how they advise the plans that set up their terms.

THE COURT: --

(Simultaneous conversation)

1 MR. DUNLAP: There's also no reason here --2 yes, Your Honor. 3 THE COURT: Where -- where does that -plaintiff's allegation that -- that patients are being 4 5 deprived drugs come from them. I'm not --MR. DUNLAP: We don't believe that it's 6 7 consistent with any of the documents that they attach to their complaints. 8 9 THE COURT: Okay. 10 MR. DUNLAP: If you look at their complaint, Your Honor, it's -- it's based largely on and cites to 11 12 a presentation --13 THE COURT: Right. 14 MR. DUNLAP: -- that a company called Express Scripts gave to a potential client, to a 15 potential health plan. Not a presentation given --16 given by Save On. 17 18 But in that program, the Express Scripts 19 employee describes generally how the program works. 20 And that -- that program makes clear -- that 21 presentation makes clear that if the patient enrolls in a program like CarePath, then it consents to 22 23 monitoring of that account by the plan, then the plans 24 will provide the drugs at no cost to the patients.

And you heard our friend on the other side

talk about engineering false denials of coverage. But if you look at the actual cited materials, and we do go into this in the motion to dismiss papers. That's not accurate.

What it says is, if someone goes to a pharmacy, and these are online pharmacies, by and large, who is not enrolled in a CarePath like program and says I want to buy this drug. The plans, again, not Save On, but the plan is structured to say, wait a minute, before you buy this drug, because you have this high co-pay, please call Save On and they will walk you through what the plan terms are.

At that point, Save On explains to them if they sign up for the program, and they consent to monitoring, then they get the drug for free. If they don't, they can still sign up for the program, but they will be responsible for the co-pays. And vir -- I think everyone, as far as I know, then signs up for the co-pay assistance program like CarePath and gets their drug for free.

So, that's what the presentation says.

There's absolutely nothing in there that says that

patients are being denied coverage. Or -- or being -
of their drugs, ultimately. Or being denied access to

their drugs or being charged large amounts for their

25

1 drugs. To the contrary, the whole program is designed to reduce and eliminate cost to the patient so they 2 3 can get these drugs. The problem J&J has with this is that they 4 5 wind up spending more money. Not that the patients wind up spending more money or are being denied their 6 7 drugs. 8 THE COURT: Okay. 9 MR. DUNLAP: But there -- there's two additional questions. So, I made the point that we 10 11 don't think there's any reason to think a brief pause here to let the Court resolve the motion to dismiss 12 13 would be overly long. 14 As my friend on the other side said, we've agreed to a very brisk briefing schedule. We got 15 their opposition yesterday --16 (Simultaneous conversation) 17 18 THE COURT: That doesn't --19 MR. DUNLAP: -- we'll be replying --THE COURT: 20 -- effect the date of -- of --21 that doesn't effect the date of decision. 22 MR. DUNLAP: That's right, Your Honor. 23 was just saying that there are two parts to it.

There's how long it takes the briefing to go in, which

is happening very quickly. And then the second part

is, you say how long it will take --

THE COURT: Right.

MR. DUNLAP: -- the Court to resolve the motion. And we're not aware of anything that we believe would take an extra ordinarily long time here. So, we don't think there's any harm that they've articulated for waiting for the Court to rule on the motion.

And then the -- the last substantive point is that ordering the early discovery that J&J seeks here we think would be a big waste of resources. So, to be clear, J&J is going after Save On hammer and tongs in this case. It's not just suing for damages. As I said, it wants to enjoin Save On from operating. It's asked a slew of trade groups to come in as amici on the motion to dismiss.

And we know that the discovery is going to be asking for here is going to be wide-ranging and aggressive. And we know that because they sent us purported requests the same day it served its complaint. They served forty-two requests. Most of which are just blunder busts.

They want everything that Save On has concerning CarePath or anyone enrolled in it. All documents concerning Save On's relationships with

various third parties. Anything Save On used to promote its services. Anything we exchange with any clients about its services. And that's thousands of clients.

And they want reams of data for every participant of every plan that Save On advised who signed up for co-pay assistance. And we're talking about hundreds of thousands of patients going back to 2017.

This is a massive amount of information.

And we submit that it wouldn't be appropriate to let

Johnson & Johnson go off on this type of fishing

expedition which would inevitably lead to hard thought

discovery disputes, draining party resources, tying up

Your Honor with protracted motion practice. When

Johnson & Johnson's claims very well may not survive

the pending motion to dismiss.

And just finally, briefly, procedurally, we're glad to proceed however Your Honor wants, of course. But we think the best way to prevent this premature discovery is simply to hold off on scheduling the Rule 16 conference.

You have the discretion to schedule it when you think best. Johnson & Johnson wants you to schedule it now which would then put the burden on us

to try to then move to say, discovery. But we don't think that's proper because Johnson & Johnson has failed to show any reason why you should use your discretion to schedule the conference now.

And we also think it's inefficient. You can avoid motion practice simply by waiting to schedule the conference until there's a ruling on the pending motion. So, we think that's the most efficient path forward and ask you not to schedule the Rule 16 conference at this time.

and -- and I think at least local counsel is very aware that our motion lists are extremely backed up. So, my considerations are in a much more practical sense rather than the wait or lack of wait with respect to prejudice to the plaintiff. Is to whether or not potentially in a year or eighteen months, how much time do I lose in discovery.

Because I think this is a case of public interest, I'm -- I understand the Local Rule 16.1 gives me some amount of discretion. I would prefer to have briefing on the docket with respect to a stay.

So, I'd ask that defense prepare a motion to stay obviously including the arguments today and any further argument so that the docket recognizes that

1 there's a motion to stay and that I have all the information I need. If in fact, I need oral argument 2 on that, I will schedule it. 3 We can meet and confer and have your own 4 5 briefing schedule on that. MR. MANGI: Your Honor, Adeel Mangi for the 6 7 plaintiff. Could we request, Your Honor, that the Court set a date in the very near future, say a week 8 from now for that motion to be on file? 10 THE COURT: You mean for the defense to file 11 a motion to stay? 12 MR. MANGI: Yes, Your Honor, so we can get 13 that, you know, filed and resolved promptly. 14 THE COURT: Yeah -- no. I'm not -- I'm not gonna do that. I'm -- the parties are gonna meet and 15 confer and draft a schedule and get it to me by the 16 end of the week. I don't -- I hope that defense isn't 17 18 going to engage in some kind of delayed briefing schedule on that in good faith. Understand? 19 20 MR. DUNLAP: Yes, Your Honor, it's Andrew 21 Dunlap. 22 THE COURT: Yes. 23 MR. DUNLAP: I -- I can tell you we will absolutely not delay -- we will want to take account 24

of the fact that we are briefing our substantive reply

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Hearing 22-cv-2632, August 16, 2022 motion over the next two weeks. But we're glad to get a motion to Your Honor as quickly as we can after that, if that works. THE COURT: Yeah. I'm gonna let you meet and confer on a schedule. But as I said, don't -don't -- don't string this out just for the sake of stringing it out because I will obviously know that. MR. DUNLAP: Understood, Your Honor. MR. GREENBAUM: Your Honor, this is Jeff Greenbaum. Could Your Honor set a -- an outside date for the Rule 16 conference so we know what -- what they're seeking to stay because without that, there's -- there's no like, guidance out there as to what is being stayed. THE COURT: What do you mean, Jeff? I'm not --(Simultaneous conversation) MR. GREENBAUM: In other words --THE COURT: -- if I set a date for a Rule 16 and there's a motion to stay, I'll have to decide the motion to stay -- to stay prior to the Rule 16 conference.

MR. GREENBAUM: Correct. I -- I -- I was -just thought -- thought that might be a way of setting it up.

THE COURT: No, I'm gonna keep tight track 1 2 I'm gonna notice every mo -- movement. 3 MR. GREENBAUM: Okay. THE COURT: So, nobody will be 4 5 disadvantaged. But I just want all the parties to know, and I know you already know this. That motions 6 7 are not moving as quickly as you anticipate. So, that -- that's gonna weigh very heavily on me. I don't 8 9 want to get into a case that's two years old and start 10 discovery then. 11 If there's an interim solution that you can work out, I encourage you to discuss that a well. 12 Perhaps, limited discovery. That's a suggestion. 13 14 It's not an order. Other than that, I'll consider the motion to stay when it's fully briefed. All right 15 folks. 16 17 MR. DUNLAP: Thank you, Judge. 18 MR. GREENBAUM: All right. Thank you. 19 MR. WOHLFORTH: Thank you very much, Your Honor. 20 21 MR. MANGI: Thank you, Your Honor. Thank you. Bye, bye. 22 THE COURT: 23 MR. DUNLAP: Bye, bye. (Conclusion of proceedings) 24

Hearing 22-cv-2632, August 16, 2022

Certification

I, Eileen M. Zakrzewski, Transcriptionist, do hereby certify that the 27 pages contained herein constitute a full, true, and accurate transcript from the official electronic recording of the proceedings had in the above-entitled matter; that research was performed on the spelling of proper names and utilizing the information provided, but that in many cases the spellings were educated guesses; that the transcript was prepared by me or under my direction and was done to the best of my skill and ability.

I further certify that I am in no way related to any of the parties hereto nor am I in any way interested in the outcome hereof.

/s/Eileen M. Zakrzewski
Signature of Approved Transcriber

August 31, 2022
Date

KING TRANSCRIPTION SERVICES, LLC 3 South Corporate Drive, Suite 203 Riverdale, NJ 07457 (973)237-6080